Idiopathic Pulmonary Fibrosis
United Therapeutics’ Tyvaso Succeeds in Phase 3 IPF Trial, Marking Major Advance in Lung Disease Treatment
Tyvaso; United Therapeutics; idiopathic pulmonary fibrosis; IPF; Phase 3 trial; TETON-2; lung disease; forced vital capacity; FVC; clinical trial; FDA; nebulized treprostinil
PureTech Spins Out Celea Therapeutics to Advance IPF Drug Candidate
PureTech; Celea Therapeutics; spin-out; lung disease; idiopathic pulmonary fibrosis; IPF; deupirfenidone; LYT-100; Sven Dethlefs; phase 3 trial
Pliant Therapeutics Discontinues Phase 2b/3 Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis Due to Safety Concerns
Pliant Therapeutics, bexotegrast, BEACON-IPF trial, idiopathic pulmonary fibrosis (IPF), safety concerns, clinical trial discontinuation
Boehringer Ingelheim’s Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment
Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity
Pliant Therapeutics Halts Phase 2b/3 Idiopathic Pulmonary Fibrosis Trial Following Safety Committee Recommendation
Pliant Therapeutics, bexotegrast, idiopathic pulmonary fibrosis (IPF), BEACON-IPF trial, clinical trial suspension, Data Safety Monitoring Board (DSMB)
Pliant Therapeutics Halts Key Fibrosis Drug Trial, Stock Plummets Amid Uncertainty
Pliant Therapeutics, bexotegrast, idiopathic pulmonary fibrosis, BEACON-IPF trial, clinical trial pause, stock crash, Data Safety Monitoring Board
Eli Lilly and Mediar Therapeutics Collaborate on Novel IPF Treatment with $780M+ Deal
Eli Lilly, Mediar Therapeutics, Idiopathic Pulmonary Fibrosis (IPF), MTX-463, WISP1 antibody, fibrosis treatment, licensing agreement, clinical trials.
PureTech’s Deupirfenidone Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Patients
Deupirfenidone, Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Forced Vital Capacity (FVC), ELEVATE IPF Phase 2b Trial, PureTech Health
PureTech’s Deupirfenidone (LYT-100) Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Phase 2b Trial
PureTech Health, Deupirfenidone (LYT-100), Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Phase 2b Trial, ELEVATE IPF Trial, Pulmonary Fibrosis Treatment
Boehringer Ingelheim Prepares NDA Filing for Pulmonary Fibrosis Drug After Positive Phase 3 Results
Boehringer Ingelheim, pulmonary fibrosis, NDA filing, Phase 3 data, nerandomilast, idiopathic pulmonary fibrosis (IPF)